Eucrates Biomedical Acquisition Corp.

Eucrates Biomedical Acquisition Corp. (Nasdaq: EUCR) is a blank-check company formed to pursue an acquisition in the biomedical and life-sciences sector. The SPAC completed its initial public offering in 2022 and filed an 8-K with the SEC on October 24, 2022, under accession number 0001104659-22-110938. Targeting opportunities in the broader healthcare and biomedical space, EUCR is one of a wave of sector-focused SPACs that came to market during the 2021–2022 cycle. For complete filing history, deal status, sponsor details, and real-time alerts on EUCR, sign up for full access at SpacDesk.